| Literature DB >> 32990835 |
Irfana Muqbil1,2, Sabiha Fatima3, Asfar S Azmi4, Ashwag Saleh Alsharidah5, Shahida Aziz Khan6, Feda Aljaser7, Naheed Banu8,9.
Abstract
Free radical involvement in initiation, promotion and progression of carcinogenesis, implicates that scavengers of free radicals may act as inhibitors in the carcinogenic process. Melatonin, an antioxidant was used in the present study to evaluate its effectiveness on skin carcinogenesis induced by DMBA both with and without chronic restraint stress (CRS). Fifty Swiss albino young male rats were divided into five groups of 10 rats each as controls, topical DMB alone, Pre CRS-DMBA, melatonin DMBA and Pre-CRS-DMBA-melatonin treated groups. After 18 weeks blood was collected along with liver and skin samples. These were used for antioxidant enzyme assay, DNA damage and fluorescent spectra analysis. Melatonin showed antioxidant potential in combatting DMBA induced skin carcinogenesis measured by free radical scavenging enzymes and in vivo antioxidant status, DNA damage. Sensitive detection of the DMBA induced micro biochemical changes was possible by fluorescent spectroscopy from the transformed ratio of fluorescent intensity (F1 530 nm/630 nm) otherwise found constant for normal tissues. By melatonin treatment this ratio was similar to control values. The decreased antioxidant biochemical parameters depicting oxidative stress were comparable to comet assay and fluorescent studies, endorsing the chemo-preventive efficacy of melatonin against skin carcinogenesis caused by DMBA. CRS pre-exposure diminished the chemo-preventive/antioxidant ability of melatonin and the results were same as DMBA alone treatment, showing stress affected both cancer development and chemoprevention. CRS decreased the antioxidant potential of melatonin. Hence, managing stress could be perceived in cancer chemoprevention. Further studies focusing on stress reduction are needed.Entities:
Keywords: Carcinogenesis; DMBA; Melatonin; Oxidative stress; Restraint stress
Mesh:
Substances:
Year: 2020 PMID: 32990835 PMCID: PMC7522450 DOI: 10.1007/s12032-020-01422-5
Source DB: PubMed Journal: Med Oncol ISSN: 1357-0560 Impact factor: 3.064
Circulatory activities of enzymatic antioxidants SOD, Glutathione-S-transferase (GST), CAT and GR after treatment with DMBA alone, DMBA-melatonin, and pre-stress DMBA and prestress DMBA melatonin treatment
| Groups | SOD | GST | CAT | GR |
|---|---|---|---|---|
| Untreated Control | 5.21 ± 0.06 | 2.53 ± 0.03 | 29.89 ± 0.46 | 20.09 ± 0.37 |
| DMBA alone | 1.52 ± 0.02* | 1.08 ± 0.02* | 19.18 ± 0.54* | 8.40 ± 0.26* |
| Pre-stress-DMBA | 0.50 ± 0.01*# | 0.32 ± 0.01*# | 9.45 ± 0.53**# | 4.78 ± 0.34**# |
| DMBA-Melatonin | 4.05 ± 0.03# | 1.82 ± 0.01# | 25.76 ± 0.64# | 15.96 ± 0.51# |
| Prestress-DMBA Melatonin | 2.80 ± 0.02** | 1.25 ± 0.01** | 14.17 ± 0.25** | 9.87 ± 0.35** |
Data represents mean ± S.E.M. of 10 animals in each group
*p < 0.01 significant when compared to control group
#p < 0.05 significant, when compared to DMBA alone group
**p < 0.05 significant when compared to DMBA-Mlt group. SOD values are expressed as Units/mg protein. One unit of enzyme was defined as the amount of enzyme that caused 50% inhibition of pyrogallol autoxidation
Plasma levels of reduced glutathione (GSH) and malondialdehyde (MDA) after treatment with melatonin in DMBA alone and pre-stress DMBA treated animals
| Groups | Reduced glutathione (µmol GSH/mg protein) | Lipid peroxidation (nmoles MDA formed/mg protein) |
|---|---|---|
| Untreated control | 5.21 ± 0.06 | 2.53 ± 0.03 |
| DMBA alone | 1.52 ± 0.02* | 1.08 ± 0.02* |
| Prestress-DMBA | 0.50 ± 0.01*# | 0.32 ± 0.01*# |
| DMBA-Melatonin | 4.05 ± 0.03# | 1.82 ± 0.01# |
| Prestress-DMBA Melatonin | 2.80 ± 0.02** | 1.25 ± 0.01** |
Data represents mean ± S.E.M. of 10 animals in each group
*p < 0.01, significant when compared to control
#p < 0.05, significant when compared to DMBA alone group
**p < 0.05, significant when compared to DMBA-Mlt group
Fig. 1Emission spectra of plasma of control, DMBA alone, pre-stress-DMBA, DMBA-melatonin and pre-stress-DMBA melatonin treated samples on excitation at 400 nm
Fig. 2The emission spectra of erythrocyte samples obtained from control, DMBA alone, pre-stress-DMBA, DMBA-melatonin and pre-stress-DMBA melatonin treatments after excitation at 400 nm
Fig. 3Erythrocyte membrane emission spectra of control, DMBA alone, pre-stress-DMBA-melatonin and pre-stress-DMBA melatonin treated samples on excitation at 400 nm
Emission characteristics of Plasma, erythrocyte and erythrocyte membrane of control and experimental groups of rats during fluorescent spectral analysis excited at 400 nm
| Groups | (FI 530/630) | (FI 530/630) | (FI 530/630) |
|---|---|---|---|
| Untreated Control | 2.02 ± 0.14 | 2.61 ± 0.21 | 1.20 ± 0.16 |
| DMBA alone | 0.70 ± 0.07* | 0.24 ± 0.06* | 1.51 ± 0.008* |
| Prestress-DMBA | 0.51 ± 0.03*# | 0.19 ± 0.07*# | 1.82 ± 0.05*# |
| DMBA-Melatonin | 1.76 ± 0.04# | 1.75 ± 0.12# | 1.30 ± 0.10# |
| Prestress DMBA-Melatonin | 0.92 ± 0.012** | 0.5 ± 0.05** | 1.42 ± 0.03** |
Data represents mean ± S.E.M. of 10 animals in each group
*p < 0.01, significant when compared to control
#p < 0.05, significant when compared to DMBA alone group
**p < 0.05, significant when compared to DMBA-Mlt group
##p < 0.05, significant when compared to DMBA-Res group
Fig. 4a–c DNA damaging effect of DMBA alone, pre-stress-DMBA, DMBA-melatonin and pre-stress-DMBA melatonin exposure, on the peripheral lymphocytes (a), liver (b) and skin cells (c) of rats. The rats were exposed to chronic restraint stress (3 h/day) for 10 days, or topically treated with 0.5% DMBA in sesame oil (twice a week) for 18 days either alone or after exposure to stress, DMBA-melatonin and pre-CRS-DMBA-melatonin as described in Sect. 2. Untreated controls were also run simultaneously. Values reported are as mean ± S.E.M. of ten animals in each group
Fig. 5Single cell gel electrophoresis of rat skin cells showing Comets (100x) after treatments with 0.5% DMBA, pre-stress and melatonin treatments as described in Sect. 2; a Untreated control, b DMBA treated, c Pre-stress DMBA, d DMBA-melatonin, e pre-stress DMBA melatonin